Format

Send to

Choose Destination
J Comp Eff Res. 2018 Aug;7(8):785-795. doi: 10.2217/cer-2018-0005. Epub 2018 Jun 4.

Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.

Author information

1
Department of Health Economics, Fudan University, Shanghai, China.
2
Health Economics and Outcomes Research Ltd, Cardiff, UK.
3
Health Economics & Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Shanghai, China.
4
World Wide Health Economics & Outcomes Research, Bristol-Myers Squibb Company, Princeton, New Jersey, USA.
5
School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Abstract

Aim: To evaluate the cost-effectiveness of the novel all-oral direct-acting antiviral regimen daclatasvir + asunaprevir (DUAL), versus interferon-based regimens for the treatment of chronic hepatitis C virus genotype 1b infection. Methods: Inputs for a lifetime Markov model were sourced from clinical trials and published literature. Outputs include disease management costs, life expectancy, quality-adjusted life-years and cost-effectiveness. Sensitivity analyses assessed the drivers of cost-effectiveness and sustained virologic response thresholds at which DUAL is cost-saving. Results: DUAL was associated with discounted incremental quality-adjusted life-years of 1.29-3.85 and incremental life-years of 0.85-2.59 per patient, with discounted lifetime cost savings of USD$1415-8525. Associated sustained virologic response rates could fall to 45.1-84.8%, while remaining dominant. Conclusion: Treatment with DUAL provides significant clinical benefit, while accruing lower lifetime costs.

KEYWORDS:

cost–effectiveness; daclatasvir + asunaprevir; hepatitis C

PMID:
29860879
DOI:
10.2217/cer-2018-0005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center